Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy

Investigator: Jorge Darcourt, MD

Study Coordinator: Syed Muhammad Saad

Status: Enrolling Number: NCT03547973

Phone: 281.276.5268

Protocol Number: Pro00021842


This is an international, multi-center, open-label, phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 /PD-L1 based immunotherapy. At least 140 patients are anticipated to be enrolled across approximately 70 sites from North America, Europe and Asia. UNDER TEMPORARY HOLD FROM SPONSOR DUE TO COVID19
More to Explore